Medical Developments International Limited (AU:MVP)
ASX:MVP
Want to see AU:MVP full AI Analyst Report?
MVP Stock Chart & Stats
AU$0.55
<AU$0.01(1.18%)
At close: 4:00 PM EST
AU$0.55
<AU$0.01(1.18%)
Day’s Range― - ―
52-Week RangeAU$0.37 - AU$0.77
Previous CloseN/A
Volume7.44K
Average Volume (3M)118.82K
Market Cap
AU$42.81M
Enterprise ValueAU$29.83M
Total Cash (Recent Filing)AU$16.88M
Total Debt (Recent Filing)AU$3.34M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding112,658,325
10 Day Avg. Volume79,692
30 Day Avg. Volume118,816
Financial Highlights & Ratios
PEG Ratio-6.86
Price to Book (P/B)1.17
Price to Sales (P/S)1.65
P/FCF Ratio-132.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.85Price Target Upside54.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$42.80M
Bulls Say, Bears Say
Bulls Say
Pain Management MomentumSustained 18% growth in the core Pain franchise reflects durable product-market fit across hospitals, ambulance and pharmacy channels. Higher volumes and pricing indicate repeatable demand and pricing power that can underpin revenue stability and margin expansion over the next 2–6 months.
Strong Gross MarginA 75%+ gross margin signals structural product-level profitability from Penthrox and device sales, implying efficient manufacturing or high value-add. This provides buffer against cost inflation and supports reinvestment into commercial/medical evidence programs over the medium term.
Low Leverage And Cash BufferVery low financial leverage with A$16.9m cash and positive operating cash flow improves runway for regulatory launches and partner transitions. The balance sheet supports continued commercial investment and evidence generation without immediate refinancing risk over the next several quarters.
Bears Say
Cash Flow DeteriorationSeverely negative FCF growth signals weakening cash conversion despite revenue gains. Over 2–6 months this constrains funding for market expansion, medical studies and partner rollouts, increasing reliance on the cash buffer and raising execution risk if trends persist.
Weak ProfitabilityExtremely low net and EBIT margins indicate the business currently struggles to convert gross profitability into operating earnings. This limits capacity to generate sustainable shareholder returns and makes the company sensitive to margin headwinds like FX, tariffs, or higher commercial spend.
Respiratory Segment WeaknessStructural weakness in Respiratory, notably a 16% US decline, reduces revenue diversification and raises concentration risk on Pain products. Persistent respiratory softness over the next several quarters will pressure group growth and margins, and complicate forecasting and resource allocation.
Medical Developments International Limited News
MVP FAQ
What was Medical Developments International Limited’s price range in the past 12 months?
Medical Developments International Limited lowest share price was AU$0.36 and its highest was AU$0.77 in the past 12 months.
What is Medical Developments International Limited’s market cap?
Medical Developments International Limited’s market cap is AU$42.81M.
When is Medical Developments International Limited’s upcoming earnings report date?
Medical Developments International Limited’s upcoming earnings report date is Aug 20, 2026 which is in 69 days.
How were Medical Developments International Limited’s earnings last quarter?
Medical Developments International Limited released its earnings results on Feb 18, 2026. The company reported -AU$0.002 earnings per share for the quarter, beating the consensus estimate of -AU$0.014 by AU$0.012.
Is Medical Developments International Limited overvalued?
According to Wall Street analysts Medical Developments International Limited’s price is currently Undervalued.
Does Medical Developments International Limited pay dividends?
Medical Developments International Limited pays a Semiannually dividend of AU$0.019 which represents an annual dividend yield of N/A. See more information on Medical Developments International Limited dividends here
What is Medical Developments International Limited’s EPS estimate?
Medical Developments International Limited’s EPS estimate is >-0.01.
How many shares outstanding does Medical Developments International Limited have?
Medical Developments International Limited has 112,658,325 shares outstanding.
What happened to Medical Developments International Limited’s price movement after its last earnings report?
Medical Developments International Limited reported an EPS of -AU$0.002 in its last earnings report, beating expectations of -AU$0.014. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medical Developments International Limited?
Currently, no hedge funds are holding shares in AU:MVP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medical Developments International Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.85 (54.55% Upside)
AU$0.85 (54.55% Upside)
Blogger Sentiment
Bullish
AU:MVP Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.67%
12-Months-Change
Fundamentals
Return on Equity
-0.79%
Trailing 12-Months
Asset Growth
-2.70%
Trailing 12-Months
Company Description
Medical Developments International Limited
Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.
MVP Stock 12 Month Forecast
Average Price Target
AU$0.85
▲(54.55% Upside)
Technical Analysis
Options Prices
Currently, No data available
---